Sellas, Life

Sellas Life Sciences: REGAL Hits Its Survival Mark, but the FDA Filing Is Still a Plan

Published on 11/18/2026 at 02:20 | Editorial boerse-global.de
Sellas' GPS met its primary overall survival endpoint in AML, with a BLA submission planned for the first half of 2027 pending FDA talks.
Sellas Life Sciences Illustration mit AI erstellt.

Sellas Life Sciences has cleared the clinical hurdle that mattered most. The company reported that its pivotal REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) met its primary endpoint on overall survival — a result that shifts investor attention from "will the data hold up?" to "can this be turned into an approval pathway?"

The numbers are unambiguous. Median overall survival reached 24.0 months on GPS versus 14.7 months with the best available treatment, a 41% reduction in the risk of death. The hazard ratio came in at 0.59, with a two-sided p-value of 0.035 — statistically significant. Because the endpoint measures how long patients live rather than merely whether they respond to therapy, the readout rests on the hardest clinical ground a study can offer.

Sellas also addressed tolerability in the mandatory disclosure filed today, describing GPS as generally well tolerated with no new safety signals identified. That gives the package both an efficacy and a safety dimension.

A regulatory plan, not a regulatory agreement

What the company did not report is a filing. Sellas said it will hold talks with the U.S. Food and Drug Administration about an accelerated submission strategy, and that it is preparing a biologics license application (BLA) for the first half of 2027. That date is the key anchor for the next phase — but it describes a corporate intention, not an arrangement already agreed with the agency. A trial hitting its endpoint does not by itself deliver an approval, and the distinction between the two should not be glossed over.

The central variable, then, is whether the announced approach proves workable in practice. Disclosures that flesh out the submission route, or confirm progress in preparing it, would carry more weight than a restatement of the study win.

Should investors sell immediately? Or is it worth buying Sellas Life Sciences?

Cash on hand and the cost of getting there

Funding the preparatory work is a separate question from the science. As of September 30, 2026, Sellas reported cash and cash equivalents of $134.7 million. That balance is relevant to the work ahead, though on its own it says nothing definitive about how long the company's runway extends.

The loss picture belongs alongside it. Sellas posted a net loss of $10,091 million for the third quarter of 2026, compared with $6.8 million in the year-earlier period. Clinical success and financial position answer different questions: the study result speaks to the candidate's efficacy, the figures to the company's ongoing operating costs. Neither substitutes for an assessment of future financing needs.

What would strengthen the case — and what would not

In the favorable scenario, Sellas converts the survival benefit into an FDA-aligned submission strategy, turning a positive study into a more concrete development path. Progress in those discussions and in application preparation would chip away at the uncertainty surrounding the next step. The bull case, in other words, is not the trial result alone; it is that Sellas advances that result through the regulatory process and funds the required work.

The serious counterargument does not dispute the endpoint. It concerns the distance between the result and the sought-after application. Should the announced approach fail to hold up, expectations for timing would need revisiting: the survival advantage would remain a study finding, but its commercial significance could materialize later than the optimistic case assumes. Treating the clinical win as an already-completed regulatory process would be the costliest mistake an investor could make here.

The calendar ahead

The prepared BLA submission in the first half of 2027 remains the reference point. Before then, any statements on the planned FDA alignment could move the assessment, provided Sellas reports genuine progress. A separate scheduled event — presentation of Phase 2 data for tambiciclib (SLS009) at the ASH annual meeting from December 12 to 15, 2026 — involves a different asset and does not answer the regulatory question hanging over GPS.

For now, the investment case rests on the combination of a delivered survival endpoint and a submission strategy still to be executed. The next meaningful step would be clarity on that pathway — not another round of applause for the study result.

Ad

Sellas Life Sciences Stock: New Analysis - 18 November

Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Sellas Life Sciences analysis...

Disclaimer...
en | US81642T2096 | SELLAS | boerse | 70529099 |